Zacks.com on MSN21h
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's ...
Pulmonaryhypertensionnews.com23h
Early Winrevair trial end to allow all patients to start active treatment
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
Hosted on MSN23h
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...
appliedclinicaltrialsonline22h
Kazia Therapeutics Launches Clinical Trial Evaluating Paxalisib in Combination with Keytruda or Lynparza for the Treatment of Advanced Breast Cancer
John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...